Active Ingredient History

  • Now
Didanosine was developed by Bristol-Myers Squibb in collaboration with the NIH for the treatment of HIV-1 infections. Upon administration the drug is metabolized to the active metabolite which inhibits HIV-1 reverse transcriptase both by competing with deoxyadenosine 5'-triphosphate and by its incorporation into viral DNA. Didanosine was approved by FDA under the name Videx (among the other names).   NCATS

  • SMILES: OC[C@@H]1CC[C@@H](O1)N2C=NC3=C2N=CNC3=O
  • Mol. Mass: 236.2273
  • ALogP: -0.21
  • ChEMBL Molecule:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No
2,3-dideoxyinosine | 2',3'-dideoxyinosine | 9-[(2r,5s)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6h-purin-6-one | 9-((2r,5s)-5-hydroxymethyl-tetrahydro-furan-2-yl)-1,9-dihydro-purin-6-one | 9-((2r,5s)-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1h-purin-6(9h)-one | 9-((2s,5r)-5-hydroxymethyl-tetrahydro-furan-2-yl)-9h-purin-6-ol | bmy-40900 | ddi | ddino | didanosina | didanosine | didanosinum | dideoxyinosine | dideoxyinosine (ddi) | videx | videx ec


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue